ArticleFrontiers in pharmacology2025
Analysis of off-label drug use and its influencing factors in pediatric patients undergoing otolaryngology, head, and neck surgery.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Drugs Associated with Pediatric Cataracts: A Real-World Pharmacovigilance Study.Children (Basel, Switzerland) · 2026Article
- Exploring pediatricians' off-label prescribing behavior in China: A theory of planned behavior-based study.International journal of clinical pharmacy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To date, there are limited data regarding off-label drug use in pediatric patients undergoing otolaryngology, head, and neck surgery. This study aimed to investigate the prevalence and patterns of off-label drug use among outpatients under 18 years of age in the Otolaryngology, Head, and Neck Surgery department, and to analyze the factors influencing such usage. Methods: A retrospective collection of data was conducted based on outpatient prescriptions for patients under 18 years of age who were visited from November 2023 to October 2024. Clinical pharmacists collected and analyzed off-label drug use. Univariate and multivariate logistic regression were employed to analyze the factors associated with off-label drug use. Results: In total, 22,487 prescriptions were included, of which 2,269 were off-label, resulting in an incidence rate of off-label drug use of 10.09%. Among 2,269 off-label prescriptions, the most common type was off-label population use (2,090 instances), accounting for 92.11%. The 2,269 off-label prescriptions encompassed 2,359 records of off-label drug use. Limonene and Pinene enteric capsules had the highest frequency of off-label use, with 1,523 records, representing 64.56% of all off-label uses. Multivariate logistic regression analysis showed that patients' age (OR = 1.341, 95% CI: 1.324 ∼ 1.359, p = 0.000), number of prescribed drugs (OR = 1.597, 95% CI: 1.528 ∼ 1.671, P < 0.001), and physician title were the factors associated with off-label drug use. Attending physicians (OR = 0.555, 95%CI: 0.458 ∼ 0.673, p < 0.001), deputy chief physicians (OR = 0.770, 95%CI: 0.637 ∼ 0.930, p = 0.007), and chief physicians (OR = 0.419, 95%CI: 0.347 ∼ 0.507, p < 0.001) were less likely to have off-label drug use compared to resident physicians. Conclusion: These findings indicate that pediatric patients who are older and receive a greater variety of medications are more likely to use drugs off-label. In addition, resident physicians exhibit a higher susceptibility for off-label drug use compared to attending physicians, deputy chief physicians, and chief physicians.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.